Ryan Cohlhepp Sells 28,214 Shares of Bicara Therapeutics (NASDAQ:BCAX) Stock

Bicara Therapeutics Inc. (NASDAQ:BCAX) COO Ryan Cohlhepp sold 28,214 shares of the firm’s stock in a transaction that occurred on Wednesday, July 8th. The shares were sold at an average price of $28.98, for a total transaction of $817,641.72. Following the completion of the transaction, the chief operating officer directly owned 182,177 shares of the company’s stock, valued at approximately $5,279,489.46. The trade was a 13.41% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ryan Cohlhepp also recently made the following trade(s):

• On Thursday, July 9th, Ryan Cohlhepp sold 536 shares of Bicara Therapeutics stock. The stock was sold at an average price of $29.00, for a total transaction of $15,544.00.
• On Friday, May 15th, Ryan Cohlhepp sold 12,500 shares of Bicara Therapeutics stock. The stock was sold at an average price of $20.29, for a total transaction of $253,625.00.
• On Wednesday, April 15th, Ryan Cohlhepp sold 12,500 shares of Bicara Therapeutics stock. The shares were sold at an average price of $23.01, for a total value of $287,625.00.

Bicara Therapeutics Stock Down 2.6%

NASDAQ BCAX traded down $0.77 during trading hours on Friday, hitting $28.91. 584,437 shares of the company were exchanged, compared to its average volume of 1,011,479. The firm has a market cap of $1.90 billion, a price-to-earnings ratio of -10.40 and a beta of -0.81. The company has a 50 day moving average of $23.43 and a two-hundred day moving average of $20.10. Bicara Therapeutics Inc. has a 52-week low of $9.47 and a 52-week high of $30.99.

Bicara Therapeutics (NASDAQ:BCAX) last announced its quarterly earnings data on Monday, May 11th. The company reported ($0.93) EPS for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.21). On average, equities research analysts predict that Bicara Therapeutics Inc. will post -3.48 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts recently commented on BCAX shares. Guggenheim initiated coverage on Bicara Therapeutics in a report on Monday, May 11th. They issued a “buy” rating and a $42.00 target price on the stock. Citizens Jmp reaffirmed a “market outperform” rating and set a $31.00 price target on shares of Bicara Therapeutics in a report on Tuesday, March 31st. The Goldman Sachs Group upped their price objective on Bicara Therapeutics from $16.00 to $18.00 and gave the stock a “neutral” rating in a research report on Tuesday, May 12th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Bicara Therapeutics in a report on Wednesday, May 27th. Finally, Wedbush reissued an “outperform” rating and set a $30.00 target price on shares of Bicara Therapeutics in a research report on Tuesday, March 31st. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $30.27.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Legal & General Group Plc lifted its position in Bicara Therapeutics by 64.1% in the second quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock valued at $29,000 after acquiring an additional 1,233 shares during the last quarter. Tower Research Capital LLC TRC grew its holdings in shares of Bicara Therapeutics by 419.3% during the second quarter. Tower Research Capital LLC TRC now owns 4,788 shares of the company’s stock worth $44,000 after purchasing an additional 3,866 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Bicara Therapeutics during the fourth quarter worth about $45,000. Larson Financial Group LLC boosted its position in shares of Bicara Therapeutics by 1,015.5% in the 3rd quarter. Larson Financial Group LLC now owns 3,949 shares of the company’s stock valued at $62,000 after purchasing an additional 3,595 shares during the period. Finally, Caitong International Asset Management Co. Ltd grew its stake in Bicara Therapeutics by 385.3% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 5,775 shares of the company’s stock worth $97,000 after buying an additional 4,585 shares during the last quarter.

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.